MedTrace Logo

A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

NCT05839041 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2025-11-20

No results posted yet for this study

Summary

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atrophy secondary to age-related macular degeneration.

Conditions

  • Geographic Atrophy of the Macula
  • Macular Degeneration

Interventions

DRUG

AVD-104

Intravitreal injection

DRUG

Avacincaptad

Intravitreal injection of 2 mg avacincaptad

Sponsors & Collaborators

  • Aviceda Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • David Callanan, MD · Aviceda Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-02
Primary Completion
2026-04-30
Completion
2026-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05839041 on ClinicalTrials.gov